Samumed continues to invest in preclinical research, expanding its technology platform while deepening its primary focus on the Wnt pathway. Thus, the company now claims a diverse pipeline of programs in different stages of clinical readiness.

Lead Compound Disease Area
Lorecivivint (SM04690) Osteoarthritis of the Knee Phase 3
SM08502 Oncology – Solid Tumors Phase 1
SM07883 Alzheimer’s Disease Phase 1
SM04554 Androgenetic Alopecia Phase 3
SM04755 Tendinopathy Phase 1
Lorecivivint (SM04690) Degenerative Disc Disease Phase 1
SM09419 Oncology – Liquid Tumors (Hematological Malignancies) Phase 1
SM04646 Idiopathic Pulmonary Fibrosis Phase 1